Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
Durvalumab | Imfinzi | MEDI4736 | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 | Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, and in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma (FDA.gov). |
Pemetrexed Disodium | Alimta | LY231514|Ciambra|pemetrexed | Chemotherapy - Antimetabolite 14 | Alimta (pemetrexed disodium) is an antifolate that inhibits thymidylate synthase (NCI Drug Dictionary). |
Tremelimumab | Imjudo | CP-675,206|Ticilimumab|CP-675206 | CTLA4 Antibody 29 Immune Checkpoint Inhibitor 147 | Imjudo (tremelimumab) binds to and inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby enhancing T-cell activation by blocking CTLA4-mediated inhibition of T-cell activation (PMID: 32620213, PMID: 32586937). Imjudo (tremelimumab) is FDA approved for use in combination with Imfinzi (durvalumab) in adult patients with unresectable hepatocellular carcinoma, and in combination with Imfinzi (durvalumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung non-small cell carcinoma | sensitive | Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab | Guideline | Actionable | Combination Paraplatin (carboplatin), Alimta (pemetrexed disodium), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression >/=1% - 49% (category 1) or >/= 50% (category 2B), and negative for actionable molecular biomarkers (NCCN.org). | detail... |
CD274 positive | lung adenocarcinoma | sensitive | Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab | Guideline | Actionable | Combination Paraplatin (carboplatin), Alimta (pemetrexed disodium), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy for patients with advanced or metastatic lung adenocarcinoma, with CD274 (PD-L1) expression >/=1% - 49% (category 1) or >/= 50% (category 2B), and negative for actionable molecular biomarkers (NCCN.org). | detail... |
CD274 positive | lung large cell carcinoma | sensitive | Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab | Guideline | Actionable | Combination Paraplatin (carboplatin), Alimta (pemetrexed disodium), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy for patients with advanced or metastatic large cell lung cancer, with CD274 (PD-L1) expression >/=1% - 49% (category 1) or >/= 50% (category 2B), and negative for actionable molecular biomarkers (NCCN.org). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06008093 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab | A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON) | Recruiting | USA | 0 |
NCT05932199 | Phase Ib/II | Durvalumab + Tremelimumab Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab | Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma | Not yet recruiting | USA | 0 |
NCT04499053 | Phase II | Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab | Durvalumab and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer | Recruiting | USA | 0 |